1	The	_	DT	_	_	2	NMOD	_	_
2	Food	_	NNP	_	_	6	SBJ	_	_
3	and	_	CC	_	_	2	COORD	_	_
4	Drug	_	NNP	_	_	5	NAME	_	_
5	Administration	_	NNP	_	_	3	CONJ	_	_
6	said	_	VBD	_	_	0	ROOT	_	_
7	American	_	NNP	_	_	9	NAME	_	_
8	Home	_	NNP	_	_	9	NAME	_	_
9	Products	_	NNP	_	_	11	SBJ	_	_
10	Corp.	_	NNP	_	_	9	POSTHON	_	_
11	agreed	_	VBD	_	_	6	OBJ	_	_
12	to	_	TO	_	_	11	OPRD	_	_
13	recall	_	VB	_	_	12	IM	_	_
14	certain	_	JJ	_	_	16	NMOD	_	_
15	generic	_	JJ	_	_	16	NMOD	_	_
16	drugs	_	NNS	_	_	13	OBJ	_	_
17	that	_	WDT	_	_	18	SBJ	_	_
18	were	_	VBD	_	_	16	NMOD	_	_
19	produced	_	VBN	_	_	18	VC	_	_
20	by	_	IN	_	_	19	LGS	_	_
21	its	_	PRP$	_	_	24	NMOD	_	_
22	Quantum	_	NNP	_	_	24	NMOD	_	_
23	Pharmics	_	NNP	_	_	24	NMOD	_	_
24	unit	_	NN	_	_	20	PMOD	_	_
25	in	_	IN	_	_	24	LOC	_	_
26	Amityville	_	NNP	_	_	25	PMOD	_	_
27	,	_	,	_	_	26	P	_	_
28	N.Y	_	NNP	_	_	26	APPO	_	_
29	.	_	.	_	_	6	P	_	_

1	Quantum	_	NNP	_	_	2	SBJ	_	_
2	stopped	_	VBD	_	_	0	ROOT	_	_
3	shipping	_	VBG	_	_	2	VC	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	drugs	_	NNS	_	_	3	OBJ	_	_
6	last	_	JJ	_	_	7	NMOD	_	_
7	month	_	NN	_	_	3	TMP	_	_
8	,	_	,	_	_	3	P	_	_
9	following	_	VBG	_	_	3	TMP	_	_
10	a	_	DT	_	_	12	NMOD	_	_
11	federal	_	JJ	_	_	12	NMOD	_	_
12	investigation	_	NN	_	_	9	PMOD	_	_
13	regarding	_	VBG	_	_	12	APPO	_	_
14	information	_	NN	_	_	13	OBJ	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	company	_	NN	_	_	17	SBJ	_	_
17	supplied	_	VBD	_	_	14	NMOD	_	_
18	to	_	TO	_	_	17	PRP	_	_
19	obtain	_	VB	_	_	18	IM	_	_
20	three	_	CD	_	_	22	NMOD	_	_
21	drug	_	NN	_	_	22	NMOD	_	_
22	approvals	_	NNS	_	_	19	OBJ	_	_
23	.	_	.	_	_	2	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	FDA	_	NNP	_	_	3	SBJ	_	_
3	requested	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	recall	_	NN	_	_	3	OBJ	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	Quantum	_	NNP	_	_	14	NMOD	_	_
8	's	_	POS	_	_	7	SUFFIX	_	_
9	mioxidil	_	NN	_	_	14	NMOD	_	_
10	tablets	_	NNS	_	_	14	NMOD	_	_
11	,	_	,	_	_	14	P	_	_
12	chlorazepate	_	NN	_	_	14	NMOD	_	_
13	dipotassium	_	NN	_	_	14	NMOD	_	_
14	tablets	_	NNS	_	_	6	PMOD	_	_
15	and	_	CC	_	_	14	COORD	_	_
16	meclofenamate	_	NN	_	_	18	NMOD	_	_
17	sodium	_	NN	_	_	18	NMOD	_	_
18	capsules	_	NNS	_	_	15	CONJ	_	_
19	because	_	IN	_	_	3	PRP	_	_
20	,	_	,	_	_	22	P	_	_
21	it	_	PRP	_	_	22	SBJ	_	_
22	said	_	VBD	_	_	19	PRN	_	_
23	,	_	,	_	_	22	P	_	_
24	the	_	DT	_	_	25	NMOD	_	_
25	size	_	NN	_	_	37	SBJ	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	the	_	DT	_	_	29	NMOD	_	_
28	production	_	NN	_	_	29	NMOD	_	_
29	runs	_	NNS	_	_	26	PMOD	_	_
30	submitted	_	VBN	_	_	29	APPO	_	_
31	for	_	IN	_	_	30	PRP	_	_
32	testing	_	NN	_	_	31	PMOD	_	_
33	to	_	TO	_	_	30	PRP	_	_
34	gain	_	VB	_	_	33	IM	_	_
35	FDA	_	NNP	_	_	36	NMOD	_	_
36	approval	_	NN	_	_	34	OBJ	_	_
37	was	_	VBD	_	_	22	OBJ	_	_
38	in	_	IN	_	_	37	LOC	_	_
39	each	_	DT	_	_	40	NMOD	_	_
40	case	_	NN	_	_	38	PMOD	_	_
41	misrepresented	_	VBD	_	_	37	VC	_	_
42	as	_	IN	_	_	41	ADV	_	_
43	much	_	RB	_	_	44	AMOD	_	_
44	larger	_	JJR	_	_	42	PMOD	_	_
45	than	_	IN	_	_	44	AMOD	_	_
46	it	_	PRP	_	_	48	SBJ	_	_
47	actually	_	RB	_	_	48	ADV	_	_
48	was	_	VBD	_	_	45	SUB	_	_
49	.	_	.	_	_	3	P	_	_

1	American	_	NNP	_	_	3	NAME	_	_
2	Home	_	NNP	_	_	3	NAME	_	_
3	Products	_	NNP	_	_	10	SBJ	_	_
4	,	_	,	_	_	3	P	_	_
5	based	_	VBN	_	_	3	APPO	_	_
6	in	_	IN	_	_	5	LOC	_	_
7	New	_	NNP	_	_	8	NAME	_	_
8	York	_	NNP	_	_	6	PMOD	_	_
9	,	_	,	_	_	3	P	_	_
10	agreed	_	VBD	_	_	0	ROOT	_	_
11	to	_	TO	_	_	10	OPRD	_	_
12	recall	_	VB	_	_	11	IM	_	_
13	four	_	CD	_	_	15	NMOD	_	_
14	other	_	JJ	_	_	15	NMOD	_	_
15	products	_	NNS	_	_	12	OBJ	_	_
16	,	_	,	_	_	15	P	_	_
17	trazadone	_	NN	_	_	15	APPO	_	_
18	,	_	,	_	_	17	P	_	_
19	doxepin	_	NN	_	_	17	COORD	_	_
20	,	_	,	_	_	19	P	_	_
21	diazepam	_	NN	_	_	19	COORD	_	_
22	and	_	CC	_	_	21	COORD	_	_
23	lorazapam	_	NN	_	_	22	CONJ	_	_
24	,	_	,	_	_	12	P	_	_
25	because	_	IN	_	_	12	PRP	_	_
26	of	_	IN	_	_	25	DEP	_	_
27	concerns	_	NNS	_	_	25	PMOD	_	_
28	about	_	IN	_	_	27	NMOD	_	_
29	data	_	NNS	_	_	28	PMOD	_	_
30	submitted	_	VBN	_	_	29	APPO	_	_
31	in	_	IN	_	_	30	LOC	_	_
32	their	_	PRP$	_	_	35	NMOD	_	_
33	original	_	JJ	_	_	35	NMOD	_	_
34	approval	_	NN	_	_	35	NMOD	_	_
35	applications	_	NNS	_	_	31	PMOD	_	_
36	before	_	IN	_	_	30	LOC	_	_
37	the	_	DT	_	_	38	NMOD	_	_
38	FDA	_	NNP	_	_	36	PMOD	_	_
39	.	_	.	_	_	10	P	_	_

1	No	_	DT	_	_	3	NMOD	_	_
2	safety	_	NN	_	_	3	NMOD	_	_
3	problems	_	NNS	_	_	7	SBJ	_	_
4	with	_	IN	_	_	3	NMOD	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	products	_	NNS	_	_	4	PMOD	_	_
7	are	_	VBP	_	_	12	OBJ	_	_
8	known	_	VBN	_	_	7	VC	_	_
9	,	_	,	_	_	12	P	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	FDA	_	NNP	_	_	12	SBJ	_	_
12	said	_	VBD	_	_	0	ROOT	_	_
13	.	_	.	_	_	12	P	_	_

1	An	_	DT	_	_	3	NMOD	_	_
2	FDA	_	NNP	_	_	3	NMOD	_	_
3	spokesperson	_	NN	_	_	4	SBJ	_	_
4	said	_	VBD	_	_	0	ROOT	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	drugs	_	NNS	_	_	7	SBJ	_	_
7	are	_	VBP	_	_	4	OBJ	_	_
8	still	_	RB	_	_	7	TMP	_	_
9	available	_	JJ	_	_	7	PRD	_	_
10	under	_	IN	_	_	7	LOC	_	_
11	other	_	JJ	_	_	13	NMOD	_	_
12	brand	_	NN	_	_	13	NMOD	_	_
13	names	_	NNS	_	_	10	PMOD	_	_
14	.	_	.	_	_	4	P	_	_

1	Last	_	JJ	_	_	2	NMOD	_	_
2	month	_	NN	_	_	7	TMP	_	_
3	,	_	,	_	_	7	P	_	_
4	American	_	NNP	_	_	6	NAME	_	_
5	Home	_	NNP	_	_	6	NAME	_	_
6	Products	_	NNP	_	_	7	SBJ	_	_
7	said	_	VBD	_	_	0	ROOT	_	_
8	it	_	PRP	_	_	9	SBJ	_	_
9	was	_	VBD	_	_	7	OBJ	_	_
10	suspending	_	VBG	_	_	9	VC	_	_
11	production	_	NN	_	_	10	OBJ	_	_
12	and	_	CC	_	_	11	COORD	_	_
13	distribution	_	NN	_	_	12	CONJ	_	_
14	of	_	IN	_	_	11	NMOD	_	_
15	all	_	DT	_	_	16	NMOD	_	_
16	21	_	CD	_	_	14	PMOD	_	_
17	of	_	IN	_	_	16	NMOD	_	_
18	Quantum	_	NNP	_	_	22	NMOD	_	_
19	's	_	POS	_	_	18	SUFFIX	_	_
20	generic	_	JJ	_	_	22	NMOD	_	_
21	drug	_	NN	_	_	22	NMOD	_	_
22	products	_	NNS	_	_	17	PMOD	_	_
23	pending	_	VBG	_	_	10	ADV	_	_
24	the	_	DT	_	_	25	NMOD	_	_
25	completion	_	NN	_	_	23	PMOD	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	an	_	DT	_	_	30	NMOD	_	_
28	exhaustive	_	JJ	_	_	30	NMOD	_	_
29	internal	_	JJ	_	_	30	NMOD	_	_
30	audit	_	NN	_	_	26	PMOD	_	_
31	.	_	.	_	_	7	P	_	_

1	It	_	PRP	_	_	4	SBJ	_	_
2	also	_	RB	_	_	4	ADV	_	_
3	temporarily	_	RB	_	_	4	TMP	_	_
4	closed	_	VBD	_	_	0	ROOT	_	_
5	Quantum	_	NNP	_	_	4	OBJ	_	_
6	,	_	,	_	_	4	P	_	_
7	because	_	IN	_	_	4	PRP	_	_
8	of	_	IN	_	_	7	DEP	_	_
9	the	_	DT	_	_	11	NMOD	_	_
10	internal	_	JJ	_	_	11	NMOD	_	_
11	investigation	_	NN	_	_	7	PMOD	_	_
12	,	_	,	_	_	11	P	_	_
13	as	_	RB	_	_	11	NMOD	_	_
14	well	_	RB	_	_	11	NMOD	_	_
15	as	_	IN	_	_	11	NMOD	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	FDA	_	NNP	_	_	20	NMOD	_	_
18	's	_	POS	_	_	17	SUFFIX	_	_
19	ongoing	_	JJ	_	_	20	NMOD	_	_
20	inquiry	_	NN	_	_	11	APPO	_	_
21	.	_	.	_	_	4	P	_	_

1	In	_	IN	_	_	12	LOC	_	_
2	New	_	NNP	_	_	7	NMOD	_	_
3	York	_	NNP	_	_	7	NMOD	_	_
4	Stock	_	NNP	_	_	7	NMOD	_	_
5	Exchange	_	NNP	_	_	7	NMOD	_	_
6	composite	_	JJ	_	_	7	NMOD	_	_
7	trading	_	NN	_	_	1	PMOD	_	_
8	,	_	,	_	_	12	P	_	_
9	American	_	NNP	_	_	11	NAME	_	_
10	Home	_	NNP	_	_	11	NAME	_	_
11	Products	_	NNP	_	_	12	SBJ	_	_
12	rose	_	VBD	_	_	0	ROOT	_	_
13	75	_	CD	_	_	14	NMOD	_	_
14	cents	_	NNS	_	_	12	EXT	_	_
15	to	_	TO	_	_	12	DIR	_	_
16	$	_	$	_	_	15	PMOD	_	_
17	105	_	CD	_	_	16	NMOD	_	_
18	on	_	IN	_	_	12	TMP	_	_
19	Friday	_	NNP	_	_	18	PMOD	_	_
20	.	_	.	_	_	12	P	_	_

